CAM
ATRA icon

Cresset Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Cresset Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed -$1K – 571
2019
Q1 		$1K Buy
+1
New +$929 ﹤0.01% 1759

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cresset Asset Management's ATRA Position: Q2 2019 in Review

Cresset Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 1 share — an estimated $1K sold.

Cresset Asset Management first reported a position in ATRA in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

  • Cresset Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Cresset Asset Management sold 1 Atara Biotherapeutics share in Q2 2019, an estimated $1K.
  • Cresset Asset Management first reported a position in Atara Biotherapeutics in Q1 2019 and held it in 1 quarter.
  • Cresset Asset Management's Atara Biotherapeutics position peaked at $1K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.